The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.04, Zacks reports. Cellectis Stock Up 5.6%Shares of NASDAQ CLLS traded up $0.15 during trading hours on Friday, hitting $2.84. Acadian Asset Management LLC raised its holdings in shares of Cellectis by 132.9% during the 1st quarter. Finally, Millennium Management LLC lifted its stake in shares of Cellectis by 61.9% in the 3rd quarter. Cellectis Company Profile(Get Free Report)Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology.